$0.25
+0.02 (+10.83%)
Open$0.23
Previous Close$0.23
Day High$0.27
Day Low$0.23
52W High$21.67
52W Low$8.32
Volume—
Avg Volume386.6K
Market Cap16.74M
P/E Ratio32.36
EPS$0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+7,941.3% upside
Current
$0.25
$0.25
Target
$20.24
$20.24
$14.74
$20.24 avg
$23.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.47M | 3.50M |
| Net Income | -124,680 | -125,666 | -103,892 |
| Profit Margin | -3.0% | -2.8% | -3.0% |
| EBITDA | -157,557 | -149,483 | -127,277 |
| Free Cash Flow | -89,797 | -95,523 | -91,369 |
| Rev Growth | +15.0% | +2.0% | +12.9% |
| Debt/Equity | 1.05 | 1.12 | 1.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |